Induction treatment strategy in multiple sclerosis: a review of past experiences and future perspectives-Reference-Cited by-同舟云学术

Induction treatment strategy in multiple sclerosis: a review of past experiences and future perspectives

Published:2018-08-14 Issue:1 Volume:3 Page:
ISSN:2056-6115
Container-title:Multiple Sclerosis and Demyelinating Disorders
language:en
Short-container-title:Mult Scler Demyelinating Disord

Author:

Ruggieri Serena,Pontecorvo Simona,Tortorella Carla,Gasperini Claudio^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40893-018-0037-7.pdf

Reference46 articles.

1. D’Amico E, Ziemssen T, Cottone S. Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion. Expert Opin Pharmacother. 2017;18:1553–6.

2. Pui C-H, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166–78.

3. Van Den Broek M, Lems WF, Allaart CF. BeSt practice: The success of early-targeted treatment in rheumatoid arthritis. Clin Exp Rheumatol. 2012;30(4 SUPPL):73.

4. Pardo G, Jones DE. Correction to: the sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol. 2017;264:2375–7. https://doi.org/10.1007/s00415-017-8594-9 .

5. Edan G, Le Page E. Induction therapy for patients with multiple Sclerosis: Why? When? How? CNS Drugs. 2013;27(6):403–9.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-08

2. Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis – real-world evidence from Germany;Therapeutic Advances in Neurological Disorders;2024-01

3. Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies;Therapeutic Advances in Neurological Disorders;2024-01

4. Disease-modifying therapies;Clinical Aspects of Multiple Sclerosis Essentials and Current Updates;2024

5. The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis;Expert Review of Neurotherapeutics;2023-05-04